Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
about
Aurora Kinase Inhibitors: Current Status and OutlookA phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicA phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsAurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancerAurora B kinase is a potent and selective target in MYCN-driven neuroblastomaDiscovery of benzo[e]pyridoindolones as kinase inhibitors that disrupt mitosis exit while erasing AMPK-Thr172 phosphorylation on the spindle.A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Are Accurins the cure for Aurora kinase inhibitors?Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.The Aurora kinase inhibitors in cancer research and therapy.Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.Clinical Development of Anti-mitotic Drugs in Cancer.The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53-/- colorectal carcinoma cell lines.[(14) C]-AZD1152 drug substance manufacture: challenges of an IV-infusion dosed human mass balance study in patients.Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c
P2860
Q26770583-FE188753-E300-48E8-937C-FD99FF58D862Q33408947-33A7609B-0A26-4FD5-BB92-237B0187D296Q34464172-16177A81-2C24-4358-9375-4321A22D4600Q34817365-FABC8974-BA02-456C-8158-B1BAAA7D8DF0Q35289072-20ED64BB-65EF-4DCF-A1E5-2919BAF008A3Q35356178-15347027-29F4-4B23-B70B-38E5250B5027Q35819646-6E874FE7-0F75-4C81-A0E2-9FBD95C845BFQ36355904-AF8CAD90-403E-4418-AA77-7FDF8535A619Q37366202-022B0440-571B-4ADD-9067-CAE61F47A0E7Q38223271-4D463D0A-B582-4271-BE97-A0E17C18C54BQ38729117-C7F314D3-6E29-4734-A95C-6DE264BD7950Q38753586-3525D029-E889-46D2-9FC6-76B5E03EA5EFQ38756932-B1368101-C303-4EFF-8351-3F67748C5347Q38902059-EA281C01-876B-41FD-BE9B-4F5D9FFC3F5CQ38951017-F3AB9F63-61B3-44E9-BD5B-025A7D099CB5Q39363642-371C8201-A2C9-4970-9278-E5512197CC78Q39369349-58FC2135-9370-4057-8EFA-3EA6E2BCF68EQ42562915-90D8CF97-9286-4887-8D2C-2694FA330BB8Q47149120-013F79BF-8EDA-4635-AE4D-8F083102196AQ51508722-63A0CB62-F5C6-4914-8784-1B7DE5C138FBQ53159205-53F40011-FEB9-467B-A3FD-6F6155ECF4A0Q54303287-BEC0B0E2-0AC3-40A2-A785-335F6FAF72A6
P2860
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@en
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@nl
type
label
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@en
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@en
Phase I study of barasertib (A ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1476
Phase I study of barasertib (A ...... nts with advanced solid tumors
@en
P2093
David Wilson
Gary K Schwartz
Geoffrey I Shapiro
Ozlem Ataman
Rachel Midgley
Richard D Carvajal
Scott J Rodig
P2860
P2888
P304
P356
10.1007/S10637-012-9825-7
P577
2012-06-02T00:00:00Z